As of November 8, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of Jasper Therapeutics, Inc. The largest reported stake is Velan Capital Investment Management LP's, at 9.9%. 21 filings are on record since July 11, 2025 (Schedule 13G, August 17, 2026).
Sell to companies like Jasper Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Bank Of America Corp · Sole voting: 0 · Shared voting: 2,133,861 · Sole dispositive: 0 · Shared dispositive: 2,133,861 · SCHEDULE 13G, 2026-10-28
- · Holder: Velan Capital Investment Management LP · Percent: 9.9% · Shares: 3,363,347 · SCHEDULE 13G
- · Holder: Velan Capital Investment Management LP · Percent: 9.88% · SCHEDULE 13D/A
- · Reporting person: Integrated Core Strategies (US) LLC · Sole voting: 0 · Shared voting: 486,454 · Sole dispositive: 0 · Shared dispositive: 486,454 · SCHEDULE 13G/A, 2026-07-10
- · Holder: Morgan Stanley · Percent: 4.8% · SCHEDULE 13G/A
Jasper Therapeutics, Inc. has 21 Schedule 13D or 13G filings on record since 2025-07-11. 4 holders' latest filing reports 5% or more of voting common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Velan Capital Investment Management LP | 9.9% | 3,363,347 | SCHEDULE 13G, 2026-08-17 | 2026-08-17 |
| T. Rowe Price Investment Management, Inc. | 7.1% | 2,057,612 | SCHEDULE 13G, 2025-11-14 | 2025-09-30 |
| Bank Of America Corp | 6.4% | 2,133,861 | SCHEDULE 13G, 2026-10-28 | 2026-09-30 |
| 5.3% | 1,486,492 | SCHEDULE 13G/A, 2026-01-26 | 2026-01-23 | |
| 4.8% | 1,333,420 | SCHEDULE 13G/A, 2026-05-12 | 2026-03-31 | |
| Kingdon Capital Management, L.L.C. | 4.7% | 1,324,845 | SCHEDULE 13G/A, 2025-11-12 | 2025-09-30 |
| The Carlyle Group Inc. | 3.8% | 1,088,310 | SCHEDULE 13D/A, 2026-02-18 | 2026-02-18 |
| Qiming U.S. Healthcare Fund II, L.P. | 3.3% | 928,964 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Integrated Core Strategies (US) LLC | 1.7% | 486,454 | SCHEDULE 13G/A, 2026-07-10 | 2026-06-30 |
| BlackRock, Inc. | 1.5% | 225,605 | SCHEDULE 13G/A, 2025-07-17 | 2025-06-30 |
| Soleus Capital Management, L.P. | 1% | 276,312 | SCHEDULE 13G/A, 2026-05-08 | 2026-03-31 |
| The Goldman Sachs Group, Inc. | 0.5% | 128,862 | SCHEDULE 13G/A, 2026-05-08 | 2026-03-31 |
Holding shares or following this stake? See who's behind Jasper Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Jasper Therapeutics, Inc. and the records around it.
Jasper Therapeutics, Inc. elsewhere on the record
- Form D filing Aug 2026
- Acquisition Jul 2026
- Leadership changes Jul 2026
- Who owns it
Companies that share a holder
- Kingdon Capital Management, L.L.C. also filed stake reports on 2 other companies: enVVeno Medical Corporation (May 2026), SCYNEXIS INC (Feb 2026)
- Velan Capital Master Fund LP also filed stake reports on 2 other companies: Edesa Biotech, Inc. (Aug 2026), InspireMD, Inc. (May 2026)
- ACORN BIOVENTURES, L.P. also filed stake reports on 5 other companies: Karyopharm Therapeutics Inc. (Oct 2026), Athira Pharma, Inc. (Aug 2026), enGene Therapeutics Inc. (Jul 2026)
Watch Jasper Therapeutics, Inc.
Get an email when Jasper Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Jasper Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Jasper Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Jasper Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
25 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Velan Capital Master Fund LP | 0 | 3,037,776 | 0 | 3,037,776 | SCHEDULE 13G, 2026-08-17 |
| Velan Capital Holdings LLC | 0 | 3,037,776 | 0 | 3,037,776 | SCHEDULE 13G, 2026-08-17 |
| Velan Horizon Fund LP | 0 | 82,008 | 0 | 82,008 | SCHEDULE 13G, 2026-08-17 |
| Velan Horizon GP LLC | 0 | 82,008 | 0 | 82,008 | SCHEDULE 13G, 2026-08-17 |
| Avego Healthcare Capital, L.P. | 0 | 243,563 | 0 | 243,563 | SCHEDULE 13G, 2026-08-17 |
| Avego Healthcare Capital Holdings, LLC | 0 | 243,563 | 0 | 243,563 | SCHEDULE 13G, 2026-08-17 |
| Avego Management LLC | 0 | 243,563 | 0 | 243,563 | SCHEDULE 13G, 2026-08-17 |
| Velan Capital Investment Management LP | 0 | 3,363,347 | 0 | 3,363,347 | SCHEDULE 13G, 2026-08-17 |
| Velan Capital Management LLC | 0 | 3,363,347 | 0 | 3,363,347 | SCHEDULE 13G, 2026-08-17 |
| Morgan Adam | 0 | 3,363,347 | 0 | 3,363,347 | SCHEDULE 13G, 2026-08-17 |
| Venkataraman Balaji | 0 | 3,363,347 | 0 | 3,363,347 | SCHEDULE 13G, 2026-08-17 |
| Kapoor Vishal | 35,013 | 0 | 35,013 | 0 | SCHEDULE 13G, 2026-08-17 |
| Bank Of America Corp | 0 | 2,133,861 | 0 | 2,133,861 | SCHEDULE 13G, 2026-10-28 |
| Integrated Core Strategies (US) LLC | 0 | 486,454 | 0 | 486,454 | SCHEDULE 13G/A, 2026-07-10 |
| Millennium Management LLC | 0 | 486,933 | 0 | 486,933 | SCHEDULE 13G/A, 2026-07-10 |
| Millennium Group Management LLC | 0 | 486,933 | 0 | 486,933 | SCHEDULE 13G/A, 2026-07-10 |
| Israel A. Englander | 0 | 486,933 | 0 | 486,933 | SCHEDULE 13G/A, 2026-07-10 |
The latest filing identifies Jasper Therapeutics, Inc. by CUSIP 471871202 and gives its principal executive office as 2200 BRIDGE PKWY SUITE #102, REDWOOD CITY, CA 94065 (SCHEDULE 13G, 2026-10-28).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-11 | Kingdon Capital Management, L.L.C. | 5.1% | SCHEDULE 13G |
| 2025-07-17 | BlackRock, Inc. | 1.5% | SCHEDULE 13G/A |
| 2025-08-06 | Morgan Stanley | 5% | SCHEDULE 13G |
| 2025-09-23 | Velan Capital Investment Management LP | 9.6% | SCHEDULE 13D/A |
| 2025-11-07 | Morgan Stanley | 2.8% | SCHEDULE 13G/A |
| 2025-11-12 | Kingdon Capital Management, L.L.C. | 4.7% | SCHEDULE 13G/A |
| 2025-11-14 | Qiming U.S. Healthcare Fund II, L.P. | 3.3% | SCHEDULE 13G/A |
| 2025-11-14 | T. Rowe Price Investment Management, Inc. | 7.1% | SCHEDULE 13G |
| 2025-12-02 | Anders Hove | 6.4% | SCHEDULE 13G |
| 2026-01-26 | Anders Hove | 5.3% | SCHEDULE 13G/A |
| 2026-02-11 | Morgan Stanley | 7% | SCHEDULE 13G |
| 2026-02-12 | The Goldman Sachs Group, Inc. | 6.3% | SCHEDULE 13G |
| 2026-02-18 | The Carlyle Group Inc. | 3.8% | SCHEDULE 13D/A |
| 2026-02-25 | Integrated Core Strategies (US) LLC | 5.8% | SCHEDULE 13G |
| 2026-05-08 | The Goldman Sachs Group, Inc. | 0.5% | SCHEDULE 13G/A |
| 2026-05-08 | Soleus Capital Management, L.P. | 1% | SCHEDULE 13G/A |
| 2026-05-12 | Morgan Stanley | 4.8% | SCHEDULE 13G/A |
| 2026-07-10 | Integrated Core Strategies (US) LLC | 1.7% | SCHEDULE 13G/A |
| 2026-07-20 | Velan Capital Investment Management LP | 9.88% | SCHEDULE 13D/A |
| 2026-08-17 | Velan Capital Investment Management LP | 9.9% | SCHEDULE 13G |
| 2026-10-28 | Bank Of America Corp | 6.4% | SCHEDULE 13G |
Questions about who owns Jasper Therapeutics, Inc.
Who owns Jasper Therapeutics, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Jasper Therapeutics, Inc.: Velan Capital Investment Management LP (9.9%, Schedule 13G, filed 2026-08-17), T. Rowe Price Investment Management, Inc. (7.1%, Schedule 13G, filed 2025-11-14), Bank Of America Corp (6.4%, Schedule 13G, filed 2026-10-28) and Anders Hove (5.3%, Schedule 13G/A, filed 2026-01-26).
Who are the largest shareholders of Jasper Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Jasper Therapeutics, Inc. on this page are Velan Capital Investment Management LP (9.9%), T. Rowe Price Investment Management, Inc. (7.1%) and Bank Of America Corp (6.4%).
When did Velan Capital Investment Management LP buy into Jasper Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Velan Capital Investment Management LP on this page is the Schedule 13D/A, filed 2025-09-23, reporting 9.6%; its latest, Schedule 13G filed 2026-08-17, reports 9.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 21 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Jasper Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 28, 2026 | Leadership change: Jeet Mahal appointed, Principal Financial Officer | — | Leadership changes | Source |
| August 5, 2026 | Form D, private offering | $132M sold | Form D page | Source |
| July 17, 2026 | Leadership change: Patrick Crutcher appointed, Director | — | Leadership changes | Source |
| July 16, 2026 | Acquired Kira Pharmaceuticals | $132M | Acquisition | Source |
| May 21, 2026 | Leadership change: Christian Nolet departs | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Jasper Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.